What is the purpose of Moderna's new partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) regarding the Bundibugyo ebolavirus?

Moderna has partnered with CEPI to develop an investigational mRNA-based vaccine candidate against Bundibugyo ebolavirus (BDBV), the strain responsible for the ongoing Ebola outbreak in eastern Democratic Republic of Congo; CEPI has committed up to $50 million to support preclinical development and early clinical testing of this vaccine.

How much funding has CEPI allocated specifically for Moderna's Bundibugyo Ebola vaccine candidate, and what other BDBV vaccine efforts is CEPI supporting?

CEPI has committed up to $50 million to support preclinical development and early clinical testing of Moderna's investigational BDBV vaccine candidate; additionally, CEPI is investing up to $8.6 million for a BDBV vaccine developed by the University of Oxford and manufactured by the Serum Institute of India, and $3.2 million for a vaccine developed by the International AIDS Vaccine Initiative.

Moderna Partners with Global Health Coalition to Develop Bundibugyo Ebola Vaccine

Jun 1, 2026

Moderna secured up to $50 million from CEPI to develop a vaccine against the Bundibugyo ebolavirus strain amid an ongoing outbreak in the Democratic Republic of Congo. Additional funding from Gavi and the Pandemic Fund aims to accelerate vaccine access.

reuters

2026-06-01

Moderna Partners with Global Health Coalition to Develop Bundibugyo Ebola Vaccine

2026-08-04

Moderna begins first human trial of Bundibugyo Ebola vaccine

Moderna Partners with Global Health Coalition to Develop Bundibugyo Ebola Vaccine

FAQ